LOUISVILLE, Ky.--(BUSINESS WIRE)--PharMerica Corporation (NYSE:PMC), a national provider of institutional, specialty home infusion, and oncology pharmacy services, today announced that it has reached a voluntary civil settlement with the Department of Justice (DOJ) related to a previously disclosed investigation into allegations that, during the January 1, 2001 through December 31, 2008 time period, certain of the Company's agreements with the manufacturer of the pharmaceutical Depakote violated the False Claims Act or the Anti-Kickback Statute. The Company denied the government’s allegations and fully cooperated with the DOJ throughout this investigation.
Under the terms of the Settlement Agreement, PharMerica has agreed to pay $9.25 million to the federal government and the various plaintiff states. The Company is fully reserved for that amount. PharMerica is pleased to resolve this matter and is committed to compliance and the highest standards of ethical conduct. PharMerica remains focused on operating with integrity and delivering industry-leading performance.
PharMerica Corporation is a leading provider of pharmacy services. PharMerica serves the long-term care, hospital pharmacy management services, specialty home infusion and oncology pharmacy markets. PharMerica operates 95 institutional pharmacies, 15 specialty home infusion pharmacies and 5 specialty oncology pharmacies in 45 states. PharMerica’s customers are institutional healthcare providers, such as skilled nursing facilities, assisted living facilities, hospitals, individuals receiving in-home care and patients with cancer.